Venous thromboembolism

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Back to Top

Section editor
Benjamin Tillman, MD
Vanderbilt University
Nashville, TN, USA
LinkedIn

Are you looking for a regimen, but can't find it here? For placebo or observational studies in this condition, please visit this page. If you still can't find it, please let us know so we can add it!
Note that there is a considerable literature on using these agents in the prevention of thromboembolism associated with atrial fibrillation and mechanical heart valves. As these conditions are out of the purview of HemOnc.org, this page primarily focuses on the prevention and treatment of venous thromboembolism (VTE).

  • We have moved How I Treat articles to a dedicated page.


Other pages on HemOnc.org regarding management of deep vein thrombosis (DVT) and pulmonary embolism (PE) include:

Last updated on 2024-07-23:
24 regimens on this page
31 variants on this page


Living Interactive Systematic Reviews

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.

ACCP


ASCO


ASH


ESMO


IMWG

Current



ITAC (International Initiative on Thrombosis and Cancer)


NCCN


VTE primary prophylaxis

Apixaban monotherapy

Regimen variant #1, 10-14 days post-op

FDA-recommended dose
Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Lassen et al. 2009 (ADVANCE-1)] Not reported Phase 3 (E-switch-ic) Enoxaparin Inconclusive whether non-inferior asymptomatic and symptomatic DVT, nonfatal PE, and death from any cause during treatment (primary endpoint) Seems to have lower bleeding rate
Lassen et al. 2010 (ADVANCE-2) 2007-06-29 to 2008-11-12 Phase 3 (E-switch-ic) Enoxaparin Superior composite primary endpoint Might have lower bleeding rate

Preceding treatment

  • Total knee replacement

Anticoagulation

10- to 14-day course


Regimen variant #2, 35 days post-op

FDA-recommended dose
Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Lassen et al. 2010 (ADVANCE-3) 2007-03 to 2009-05 Phase 3 (E-switch-ic) Enoxaparin Superior composite primary endpoint Did not meet endpoint of major and clinically relevant nonmajor bleeding

Preceding treatment

  • Total hip replacement

Anticoagulation

35-day course


Regimen variant #3, 180 days

FDA-recommended dose
Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Carrier et al. 2018 (AVERT) 2014-02 to 2018-04 Phase 3 (E-esc) Placebo Superior VTE rate over 180 days (primary endpoint) Seems to have higher rate of bleeding

Anticoagulation

  • Apixaban (Eliquis) 2.5 mg PO twice per day, beginning within 24 h of initiation of chemotherapy

6-month course

References

  1. ADVANCE-1: Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 6;361(6):594-604. Erratum in: N Engl J Med. 2009 Oct 29;361(18):1814. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00371683
  2. ADVANCE-2: Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 6;375(9717):807-15. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00452530
  3. ADVANCE-3: Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23;363(26):2487-98. link to original article PubMed NCT00423319
  4. AVERT: Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS; AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019 Feb 21;380(8):711-719. Epub 2018 Dec 4. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02048865
  5. PREVAPIX-ALL: O'Brien SH, Rodriguez V, Lew G, Newburger JW, Schultz CL, Orgel E, Derr K, Ranalli MA, Esbenshade AJ, Hochberg J, Kang HJ, Dinikina Y, Mills D, Donovan M, Dyme JL, Favatella NA, Mitchell LG; PREVAPIX-ALL investigators. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024 Jan;11(1):e27-e37. Epub 2023 Nov 16. link to original article PubMed NCT02369653


Aspirin monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Rodgers et al. 2000 (PEP) 1992-1998 Phase 3 (E-esc) Placebo Superior VTE rate
Landolfi et al. 2004 (ECLAP) Not reported Phase 3 (E-esc) Placebo Seems to have superior rate of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes (primary endpoint)
Palumbo et al. 2011 (GIMEMA MM-03-05) 2006-05 to 2009-01 Phase 3 (E-switch-ic) 1. Enoxaparin
2. Warfarin; low-dose 		Did not meet primary endpoint of serious thromboembolic events, acute cardiovascular events, or sudden deaths during the first 6 months of treatment
Larocca et al. 2011 (MPRvsMEL200VTE) 2007-11 to 2009-06 Phase 3 (E-de-esc) Enoxaparin Did not meet primary endpoint of VTE incidence
Anderson et al. 2013 (EPCAT) 2007-2010 Phase 3 (E-de-esc) Dalteparin Non-inferior VTE rate at 90 days (primary endpoint)
Anderson et al. 2018 (EPCAT II) 2013-01 to 2016-04 Phase 3 (E-de-esc) Rivaroxaban Non-inferior VTE rate at 90 days (primary endpoint)
O'Toole et al. 2023 (PREVENT CLOT) 2017-04 to 2021-08 Randomized (C) Enoxaparin Non-inferior death rate at 90 days

Note: Palumbo et al. 2011 was a substudy looking at thromboprophylaxis in the thalidomide arm. Larocca et al. 2011 was also a substudy looking at thromboprophylaxis in the lenalidomide arm.

Anticoagulation

  • Aspirin 81 to 160 mg PO once per day

Various durations, see individual trials

References

  1. PEP: Rodgers A, MacMahon S, Collins R, Prentice C; Pulmonary Embolism Prevention (PEP) trial Collaborative Group. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000 Apr 15;355(9212):1295-302. link to original article PubMed
  2. ECLAP: Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004 Jan 8;350(2):114-24. link to original article PubMed
  3. GIMEMA MM-03-05: Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010 Dec 1;28(34):5101-9. Epub 2010 Oct 12. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01063179
    1. Post-hoc analysis: Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, Gentili S, Patriarca F, Nozzoli C, Levi A, Guglielmelli T, Benevolo G, Callea V, Rizzo V, Cangialosi C, Musto P, De Rosa L, Liberati AM, Grasso M, Falcone AP, Evangelista A, Cavo M, Gaidano G, Boccadoro M, Palumbo A. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010 Dec 2;116(23):4745-53. Epub 2010 Aug 31. link to original article dosing details in manuscript have been reviewed by our editors PubMed
    2. Subgroup analysis: Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, Magarotto V, Tacchetti P, Pescosta N, Cellini C, Polloni C, Evangelista A, Caravita T, Morabito F, Offidani M, Tosi P, Boccadoro M. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011 Mar 10;29(8):986-93. Epub 2011 Jan 31. link to original article PubMed
  4. MPRvsMEL200VTE: Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012 Jan 26;119(4):933-9. Epub 2011 Aug 11. link to original article PubMed NCT00551928
  5. EPCAT: Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, Fisher W, Gofton W, Gross P, Pelet S, Crowther M, MacDonald S, Kim P, Pleasance S, Davis N, Andreou P, Wells P, Kovacs M, Rodger MA, Ramsay T, Carrier M, Vendittoli PA. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013 Jun 4;158(11):800-6. link to original article PubMed ISRCTN11902170
  6. EPCAT II: Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, Pelet S, Fisher W, Belzile E, Dolan S, Crowther M, Bohm E, MacDonald SJ, Gofton W, Kim P, Zukor D, Pleasance S, Andreou P, Doucette S, Theriault C, Abianui A, Carrier M, Kovacs MJ, Rodger MA, Coyle D, Wells PS, Vendittoli PA. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018 Feb 22;378(8):699-707. link to original article PubMed NCT01720108
  7. PREVENT CLOT: O'Toole RV, Stein DM, O'Hara NN, Frey KP, Taylor TJ, Scharfstein DO, Carlini AR, Sudini K, Degani Y, Slobogean GP, Haut ER, Obremskey W, Firoozabadi R, Bosse MJ, Goldhaber SZ, Marvel D, Castillo RC. Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. N Engl J Med. 2023 Jan 19;388(3):203-213. link to original article PubMed NCT02984384


Betrixaban monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Cohen et al. 2016 (APEX-VTE) 2012-03 to 2015-11 Phase 3 (E-switch-ic) Enoxaparin Might have lower rates of VTE (primary endpoint)

Note: this APEX trial should not be confused with the one in multiple myeloma.

Anticoagulation

35- to 42-day course

References

  1. APEX-VTE: Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM; APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016 Aug 11;375(6):534-44. Epub 2016 May 27. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01583218


Enoxaparin monotherapy

Regimen variant #1, 30 mg every 12 hours

Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Geerts et al. 1996 1992-11 to 1994-11 Phase 3 (E-switch-ic) UFH Superior DVT rates No difference in major bleeding rate
Lassen et al. 2009 (ADVANCE-1)] Not reported Phase 3 (C) Apixaban Inconclusive whether non-inferior asymptomatic and symptomatic DVT, nonfatal PE, and death from any cause during treatment Seems to have higher bleeding rate
O'Toole et al. 2023 (PREVENT CLOT) 2017-04 to 2021-08 Randomized (E-esc) Aspirin Non-inferior death rate at 90 days (primary endpoint)

Preceding treatment

  • ADVANCE-1: Total knee replacement
  • The study population in Geerts et. al. were trauma patients without intracranial hemorrhage. Prophylaxis was initiated within 36 hours of the injury.

Anticoagulation

10- to 14-day course


Regimen variant #2, 40 mg daily

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Samama et al. 1999 (MEDENOX) 1996-12 to 1998-07 Phase 3 (C) 1. Placebo
2. Enoxaparin; 20 mg daily 		Superior VTE rates
Hull et al. 2010 (EXCLAIM) 2002-02 to 2006-03 Phase 3 (E-esc) Placebo Superior composite VTE rate (primary endpoint)
Erikkson et al. 2008 (RECORD1) 2006-02 to 2007-03 Phase 3 (C) Rivaroxaban Inferior composite outcome
Kakkar et al. 2008 (RECORD2) 2006-02 to 2007-04 Phase 3 (C) Rivaroxaban Inferior composite outcome
Lassen et al. 2008 (RECORD3) 2006-02 to 2006-11 Phase 3 (C) Rivaroxaban Inferior composite outcome
Palumbo et al. 2011 (GIMEMA MM-03-05) 2006-05 to 2009-01 Phase 3 (E-switch-ic) 1. Aspirin
2. Warfarin; low-dose 		Did not meet primary endpoint of serious thromboembolic events, acute cardiovascular events, or sudden deaths during the first 6 months of treatment
Turpie et al. 2009 (RECORD4) 2006-06 to 2007-10 Phase 3 (C) Rivaroxaban Seems to have inferior composite outcome
Lassen et al. 2010 (ADVANCE-3) 2007-03 to 2009-05 Phase 3 (C) Apixaban Inferior composite primary endpoint
Goldhaber et al. 2011 (ADOPT) 2007-06 to 2011-02 Phase 3 (C) Apixaban Did not meet primary endpoint of 30-day composite of death related to venous thromboembolism, pulmonary embolism, symptomatic deep-vein thrombosis, or asymptomatic proximal-leg deep-vein thrombosis
Lassen et al. 2010 (ADVANCE-2) 2007-06-29 to 2008-11-12 Phase 3 (C) Apixaban Inferior composite primary endpoint
Larocca et al. 2011 (MPRvsMEL200VTE) 2007-11 to 2009-06 Phase 3 (E-esc) Aspirin Did not meet primary endpoint of VTE incidence
Cohen et al. 2013 (MAGELLAN) 2007-12 to 2010-07 Phase 3 (C) Rivaroxaban Non-inferior VTE rate at 10 days
Kakkar et al. 2011 (LIFENOX) 2008-01 to 2010-09 Phase 3 (E-esc) Placebo Did not meet primary endpoint of death rate at 30 days
Cohen et al. 2016 (APEX-VTE) 2012-03 to 2015-11 Phase 3 (C) Betrixaban Might have higher rates of VTE
Sidhu et al. 2022 (CRISTAL) 2019-04-20 to 2020-12-18 Phase 3 (C) Aspirin Superior rate of symptomatic VTE within 90 days

Note: the APEX trial here should not be confused with the one in multiple myeloma. Larocca et al. 2011 was a substudy looking at thromboprophylaxis in the lenalidomide arm.

Preceding treatment

  • ADVANCE-2 & CRISTAL: Total knee replacement
  • ADVANCE-3 & CRISTAL: Total hip replacement

Anticoagulation

Various durations: 6 to 14 days (APEX-VTE); other (see papers for details)

References

  1. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996 Sep 5;335(10):701-7. link to original article PubMed
  2. MEDENOX: Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N; MEDENOX Investigators. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999; 341:793-800. link to original article. PubMed.
  3. RECORD2: Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008 Jul 5;372(9632):31-9. Epub 2008 Jun 24. link to original article PubMed NCT00332020
  4. RECORD1: Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2765-75. link to original article PubMed NCT00329628
  5. RECORD3: Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2776-86. link to original article PubMed NCT00361894
  6. RECORD4: Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 May 16;373(9676):1673-80. Epub 2009 May 4. link to original article PubMed NCT00362232
  7. ADVANCE-1: Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 6;361(6):594-604. Erratum in: N Engl J Med. 2009 Oct 29;361(18):1814. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00371683
  8. ADVANCE-2: Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 6;375(9717):807-15. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00452530
  9. EXCLAIM: Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010 Jul 6;153(1):8-18. link to original article PubMed NCT00077753
  10. ADVANCE-3: Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23;363(26):2487-98. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00423319
  11. GIMEMA MM-03-05: Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, Magarotto V, Tacchetti P, Pescosta N, Cellini C, Polloni C, Evangelista A, Caravita T, Morabito F, Offidani M, Tosi P, Boccadoro M. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011 Mar 10;29(8):986-93. Epub 2011 Jan 31. link to original article PubMed NCT01063179
  12. MPRvsMEL200VTE: Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012 Jan 26;119(4):933-9. Epub 2011 Aug 11. link to original article PubMed NCT00551928
  13. ADOPT: Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011 Dec 8;365(23):2167-77. Epub 2011 Nov 13. link to original article PubMed NCT00457002
  14. LIFENOX: Kakkar AK, Cimminiello C, Goldhaber SZ, Parakh R, Wang C, Bergmann JF; LIFENOX Investigators. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011 Dec 29;365(26):2463-72. link to original article PubMed NCT00622648
  15. MAGELLAN: Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013 Feb 7;368(6):513-23. link to original article PubMed NCT00571649
  16. APEX-VTE: Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM; APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016 Aug 11;375(6):534-44. Epub 2016 May 27. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT01583218
  17. CRISTAL: Sidhu VS, Kelly TL, Pratt N, Graves SE, Buchbinder R, Adie S, Cashman K, Ackerman I, Bastiras D, Brighton R, Burns AWR, Chong BH, Clavisi O, Cripps M, Dekkers M, de Steiger R, Dixon M, Ellis A, Griffith EC, Hale D, Hansen A, Harris A, Hau R, Horsley M, James D, Khorshid O, Kuo L, Lewis P, Lieu D, Lorimer M, MacDessi S, McCombe P, McDougall C, Mulford J, Naylor JM, Page RS, Radovanovic J, Solomon M, Sorial R, Summersell P, Tran P, Walter WL, Webb S, Wilson C, Wysocki D, Harris IA; CRISTAL Study Group. Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial. JAMA. 2022 Aug 23;328(8):719-727. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed ACTRN12618001879257
  18. PREVENT CLOT: O'Toole RV, Stein DM, O'Hara NN, Frey KP, Taylor TJ, Scharfstein DO, Carlini AR, Sudini K, Degani Y, Slobogean GP, Haut ER, Obremskey W, Firoozabadi R, Bosse MJ, Goldhaber SZ, Marvel D, Castillo RC. Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. N Engl J Med. 2023 Jan 19;388(3):203-213. link to original article PubMed NCT02984384


Rivaroxaban monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Erikkson et al. 2008 (RECORD1) 2006-02 to 2007-03 Phase 3 (E-switch-ic) Enoxaparin Superior composite outcome (primary endpoint)
Kakkar et al. 2008 (RECORD2) 2006-02 to 2007-04 Phase 3 (E-switch-ic) Enoxaparin Superior composite outcome (primary endpoint)
Lassen et al. 2008 (RECORD3) 2006-02 to 2006-11 Phase 3 (E-switch-ic) Enoxaparin Superior composite outcome (primary endpoint)
Turpie et al. 2009 (RECORD4) 2006-06 to 2007-10 Phase 3 (E-switch-ic) Enoxaparin Seems to have superior composite outcome (primary endpoint)
Cohen et al. 2013 (MAGELLAN) 2007-12 to 2010-07 Phase 3 (E-switch-ic) Enoxaparin Non-inferior VTE rate at 10 days (co-primary endpoint)
Anderson et al. 2018 (EPCAT II) 2013-01 to 2016-04 Phase 3 (E-esc) Aspirin Non-inferior VTE rate at 90 days (primary endpoint)
Spyropoulos et al. 2018 (MARINER) 2014-06 to 2018-01 Phase 3 (E-esc) Placebo Did not meet primary endpoint of symptomatic VTE or death due to VTE

Anticoagulation

Varying durations (see individual studies)

References

  1. RECORD2: Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008 Jul 5;372(9632):31-9. Epub 2008 Jun 24. link to original article PubMed NCT00332020
  2. RECORD1: Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2765-75. link to original article PubMed NCT00329628
  3. RECORD3: Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2776-86. link to original article PubMed NCT00361894
  4. RECORD4: Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 May 16;373(9676):1673-80. Epub 2009 May 4. link to original article PubMed NCT00362232
  5. MAGELLAN: Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013 Feb 7;368(6):513-23. link to original article PubMed NCT00571649
  6. EPCAT II: Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, Pelet S, Fisher W, Belzile E, Dolan S, Crowther M, Bohm E, MacDonald SJ, Gofton W, Kim P, Zukor D, Pleasance S, Andreou P, Doucette S, Theriault C, Abianui A, Carrier M, Kovacs MJ, Rodger MA, Coyle D, Wells PS, Vendittoli PA. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018 Feb 22;378(8):699-707. link to original article PubMed NCT01720108
  7. MARINER: Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018 Sep 20;379(12):1118-1127. Epub 2018 Aug 26. link to original article PubMed NCT02111564


VTE secondary prevention

Apixaban monotherapy

Regimen variant #1, 2.5 mg twice per day

FDA-recommended dose
Study Dates of enrollment Evidence Comparator Comparative Efficacy
Agnelli et al. 2012 (AMPLIFY-EXT) 2008-05 to 2011-07 Phase 3 (E-esc) 1. Apixaban; 5 mg twice per day Did not meet primary endpoint of symptomatic recurrent VTE or death from any cause
2. Placebo Superior symptomatic recurrent VTE or death from any cause

Preceding treatment

  • Therapeutic anticoagulation x 6-12 mo

Anticoagulation

12-month course


Regimen variant #2, 5 mg twice per day

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Agnelli et al. 2012 (AMPLIFY-EXT) 2008-05 to 2011-07 Phase 3 (E-esc) 1. Apixaban; 2.5 mg twice per day Did not meet primary endpoint of symptomatic recurrent VTE or death from any cause
2. Placebo Superior symptomatic recurrent VTE or death from any cause

Preceding treatment

  • Therapeutic anticoagulation x 6-12 mo

Anticoagulation

12-month course

References

  1. AMPLIFY-EXT: Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708. Epub 2012 Dec 8. link to original article dosing details in manuscript have been reviewed by our editors PubMed


Aspirin monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Brighton et al. 2012 (ASPIRE-VTE) 2003-05 to 2011-08 Phase 3 (E-esc) Placebo Might have superior rate of VTE recurrence (primary endpoint) No difference in bleeding rate
Becattini et al. 2012 (WARFASA) 2004-05 to 2010-08 Phase 3 (E-esc) Placebo Superior rate of VTE recurrence (primary endpoint) No difference in bleeding rate

Note: ASPIRE should not be confused with the multiple myeloma trial of the same name.

Preceding treatment

Anticoagulation

Two or more years

References

  1. WARFASA: Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012 May 24;366(21):1959-67. Erratum in: N Engl J Med. 2012 Oct 18;367(16):1573. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00222677
  2. ASPIRE-VTE: Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012 Nov 22;367(21):1979-87. Epub 2012 Nov 4. link to original article PubMed ACTRN12605000004662


Dalteparin monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Lee et al. 2003 (CLOT) 1999-05 to 2001-10 Phase 3 (E-switch-ic) Warfarin Superior rate of VTE at 6 months (primary endpoint) No difference in bleeding rate

Anticoagulation

  • Dalteparin (Fragmin) as follows:
    • Month 1: 200 IU/kg SC once per day
    • Months 2 to 6: 150 IU/kg SC once per day

6-month course

References

  1. CLOT: Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 Jul 10;349(2):146-53. link to original article PubMed
    1. Post-hoc analysis: Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005 Apr 1;23(10):2123-9. Epub 2005 Feb 7. link to original article PubMed


Enoxaparin monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Meyer et al. 2002 1995-04 to 1999-03 Phase 3 (E-switch-ic) Warfarin Might have superior composite VTE/bleeding outcome (primary endpoint)

Anticoagulation

3-month course

References

  1. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G; Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 1998 Feb 12;338(7):409-15. link to original article PubMed
  2. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002 Aug 12-26;162(15):1729-35. link to original article dosing details in abstract have been reviewed by our editors PubMed
  3. Highlow: Bistervels IM, Buchmüller A, Wiegers HMG, Ní Áinle F, Tardy B, Donnelly J, Verhamme P, Jacobsen AF, Hansen AT, Rodger MA, DeSancho MT, Shmakov RG, van Es N, Prins MH, Chauleur C, Middeldorp S; Highlow Block writing committee; Highlow Investigators. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial. Lancet. 2022 Oct 28:S0140-6736(22)02128-6. link to original article PubMed NCT01828697


Warfarin monotherapy

Regimen variant #1, standard intensity

Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Meyer et al. 2002 1995-04-02 to 1999-03-31 Phase 3 (C) Enoxaparin Might have inferior composite VTE/bleeding outcome
Lee et al. 2003 (CLOT) 1999-05 to 2001-10 Phase 3 (C) Dalteparin Inferior rate of VTE at 6 months No difference in bleeding rate

Anticoagulation


Regimen variant #2, low intensity

Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Ridker et al. 2003 (PREVENT) 1998-07-06 to 2002-12-04 Phase 3 (E-esc) Placebo Superior recurrent VTE rate (primary endpoint) No difference in major bleeding

Preceding treatment

  • Warfarin with goal INR of 2 to 3 for median of 6.5 mo

Anticoagulation

Continued indefinitely

References

  1. Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002 Aug 12-26;162(15):1729-35. link to original article PubMed
  2. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, MacKinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, Kahn SR, Kassis J, Rodger M, Hambleton J, Gent M; Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003 Aug 14;349(7):631-9. link to original article PubMed
  3. PREVENT: Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ; PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003 Apr 10;348(15):1425-34. Epub 2003 Feb 24. link to original article dosing details in manuscript have been reviewed by our editors PubMed
  4. CLOT: Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 Jul 10;349(2):146-53. link to original article PubMed
    1. Post-hoc analysis: Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005 Apr 1;23(10):2123-9. Epub 2005 Feb 7. link to original article PubMed


VTE treatment, all lines of therapy

Apixaban monotherapy

Regimen

FDA-recommended dose
Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Agnelli et al. 2013 (AMPLIFY) 2008-08 to 2012-08 Phase 3 (E-switch-ooc) Warfarin Non-inferior composite primary endpoint Lower rates of bleeding
McBane et al. 2019 (ADAM VTE) 2015-11-20 to 2017-10-02 Phase 3 (E-switch-ooc) Dalteparin Might have lower rates of major bleeding (primary endpoint)
Angelli et al. 2020 (CARAVAGGIO) 2017-04 to 2019-06 Phase 3 (E-switch-ooc) Dalteparin Non-inferior recurrent VTE (primary endpoint) Major bleeding similar in both groups

Anticoagulation

6-month course

References

  1. AMPLIFY: Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. Epub 2013 Jul 1. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00643201
  2. ADAM VTE: McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020 Feb;18(2):411-421. Epub 2019 Nov 28. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02585713
  3. CARAVAGGIO: Agnelli G, Becattini C, Meyer G, Munoz A, Huisman M, Connors J, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro M, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M, Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020 Apr 23;382(17):1599-1607. Epub 2020 Mar 29. link to original article PubMed NCT03045406


Argatroban monotherapy

Regimen

Anticoagulation

References

To be completed


Aspirin monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Weitz et al. 2017 (EINSTEIN CHOICE) 2014-03 to 2016-03 Phase 3 (C) 1. Rivaroxaban; 10 mg/day
2. Rivaroxaban; 20 mg/day 		Inferior symptomatic recurrent VTE rate Similar major bleeding

Preceding treatment

  • 6 to 12 months of a vitamin K antagonist or a direct oral anticoagulant

Anticoagulation

Up to 12-month course

References

  1. EINSTEIN CHOICE: Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017 Mar 30;376(13):1211-1222. Epub 2017 Mar 18. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT02064439


Bivalirudin monotherapy

Regimen

Anticoagulation

References

To be completed


Dabigatran monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Schulman et al. 2009 (RE-COVER) 2006-04 to 2008-11 Phase 3 (E-switch-ic) Warfarin Non-inferior composite primary endpoint Similar major bleeding

Anticoagulation

6-month course

References

  1. RE-COVER: Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 Dec 10;361(24):2342-52. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00291330
  2. RE-MEDY: Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):709-18. link to original article PubMed NCT00329238
  3. RE-COVER II: Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 Feb 18;129(7):764-72. Epub 2013 Dec 16. link to original article PubMed NCT00680186
  4. DIVERSITY: Halton J, Brandão LR, Luciani M, Bomgaars L, Chalmers E, Mitchell LG, Nurmeev I, Sharathkumar A, Svirin P, Gorbatikov K, Tartakovsky I, Simetzberger M, Huang F, Sun Z, Kreuzer J, Gropper S, Reilly P, Brueckmann M, Albisetti M; DIVERSITY Trial Investigators. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol. 2021 Jan;8(1):e22-e33. Epub 2020 Dec 5. link to original article PubMed NCT01895777


Dalteparin monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Francis et al. 2015 (DALTECAN) 2009-06 to 2011-03 Non-randomized
Young et al. 2018 (SELECT-D) 2013-09-06 to 2016-12-22 Phase 3 (C) Rivaroxaban Seems to have inferior rate of VTE recurrence Superior rates of clinically relevant non-major bleeding
Raskob et al. 2017 (Hokusai VTE Cancer) 2015-07 to 2016-12 Phase 3 (C) Edoxaban Non-inferior composite primary endpoint of VTE/major bleeding Non-inferior composite primary endpoint of VTE/major bleeding
Angelli et al. 2020 (CARAVAGGIO) 2017-04 to 2019-06 Phase 3 (C) Apixaban Non-inferior recurrent VTE Major bleeding similar in both groups

Anticoagulation

  • Dalteparin (Fragmin) as follows:
    • Month 1: 200 IU/kg SC once per day
    • Months 2 to 6 up to 12: 150 IU/kg SC once per day

6- to 12-month course

References

  1. DALTECAN: Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, Bergqvist D, Turpie AG, Ortel TL, Spyropoulos AC, Pabinger I, Kakkar AK. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost. 2015 Jun;13(6):1028-35. Epub 2015 May 10. link to original article PubMed NCT00942968
  2. Hokusai VTE Cancer: Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-624. Epub 2017 Dec 12. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02073682
  3. SELECT-D: Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018 Jul 10;36(20):2017-2023. Epub 2018 May 10. link to original article dosing details in abstract have been reviewed by our editors PubMed ISRCTN86712308
  4. ADAM VTE: McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, Perepu U, Anderson D, Gundabolu K, Kuzma C, Perez Botero J, Leon Ferre RA, Henkin S, Lenz CJ, Houghton DE, Vishnu P, Loprinzi CL. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020 Feb;18(2):411-421. Epub 2019 Nov 28. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02585713
  5. CARAVAGGIO: Agnelli G, Becattini C, Meyer G, Munoz A, Huisman M, Connors J, Cohen A, Bauersachs R, Brenner B, Torbicki A, Sueiro M, Lambert C, Gussoni G, Campanini M, Fontanella A, Vescovo G, Verso M, Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020 Apr 23;382(17):1599-1607. Epub 2020 Mar 29. link to original article PubMed NCT03045406


Edoxaban monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Büller et al. 2013 (Hokusai-VTE) 2010-01 to 2012-10 Phase 3 (E-RT-switch-ic) Warfarin Non-inferior recurrent symptomatic VTE rate (primary endpoint)
Symptomatic VTE rate: 3.2% vs 3.5%
(HR 0.89, 95% CI 0.70-1.13) 		Lower rates of bleeding
Raskob et al. 2017 (Hokusai VTE Cancer) 2015-07 to 2016-12 Phase 3 (E-RT-switch-ic) Dalteparin Non-inferior composite primary endpoint of VTE/major bleeding Non-inferior composite primary endpoint of VTE/major bleeding

Anticoagulation

3- to 12-month course

Dose and schedule modifications

References

  1. Hokusai-VTE: Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406-15. Epub 2013 Aug 31. Erratum in: N Engl J Med. 2014 Jan 23;370(4):390. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00986154
    1. Subgroup analysis: Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, Büller HR; Hokusai-VTE investigators. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 Aug;3(8):e379-87. Epub 2016 Jul 1. link to original article PubMed
  2. Hokusai VTE Cancer: Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-624. Epub 2017 Dec 12. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT02073682


Enoxaparin monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Kearon et al. 2006 (FIDO) 1998-09 to 2004-02 Phase 3 (E-switch-ic) 1. Dalteparin
2. UFH 		No difference in recurrent VTE or major bleeding

Anticoagulation

One course

References

  1. FIDO: Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M; Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 2006 Aug 23;296(8):935-42. link to original article PubMed NCT00182403


Fondaparinux monotherapy

Regimen

Anticoagulation

References

To be completed


Heparin monotherapy

UFH: UnFractionated Heparin

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Loewe & Hirsch 1947 Not reported Observational None 2.4% fatality rate due to pulmonary embolism
Kearon et al. 2006 (FIDO) 1998-09 to 2004-02 Phase 3 (C) 1. Dalteparin
2. Enoxaparin 		No difference in recurrent VTE or major bleeding

Note: In Loewe and Hirsch, heparin was administered as a deep subcutaneous injection (200 to 400 mg / 200,000 to 400,000 IU) in Pitkin menstruum every two to three days for 10 to 14 days for deep vein thrombosis and extended for one to two additional weeks for pulmonary embolism.

Anticoagulation

One course

References

  1. Loewe L, Hirsch E. Heparin in the treatment of thromboembolic disease. JAMA. 1947;133(17):1263-1268. link to original article PubMed
  2. FIDO: Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M; Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 2006 Aug 23;296(8):935-42. link to original article PubMed NCT00182403


Lepirudin monotherapy

Regimen

Anticoagulation

References

To be completed


Rivaroxaban monotherapy

Regimen variant #1, 10 mg/day

Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Weitz et al. 2017 (EINSTEIN CHOICE) 2014-03 to 2016-03 Phase 3 (E-esc) 1. Aspirin Superior symptomatic recurrent VTE rate (primary endpoint) Similar major bleeding
2. Rivaroxaban; 20 mg/day Did not meet primary endpoint of symptomatic recurrent VTE rate Similar major bleeding

Preceding treatment

  • 6 to 12 months of a vitamin K antagonist or a direct oral anticoagulant

Anticoagulation

Up to 12-month course


Regimen variant #2, 20 mg/day

Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Weitz et al. 2017 (EINSTEIN CHOICE) 2014-03 to 2016-03 Phase 3 (E-esc) 1. Aspirin Superior symptomatic recurrent VTE rate (primary endpoint) Similar major bleeding
2. Rivaroxaban; 10 mg/day Did not meet primary endpoint of symptomatic recurrent VTE rate Similar major bleeding

Preceding treatment

  • 6 to 12 months of a vitamin K antagonist or a direct oral anticoagulant

Anticoagulation

Up to 12-month course


Regimen variant #3, 20 mg/day with loading dose

Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Bauersachs et al. 2010 (EINSTEIN Acute DVT) 2007-03 to 2009-09 Phase 3 (E-switch-ic) Warfarin Non-inferior VTE recurrence (primary endpoint) Similar major bleeding
Büller et al. 2012 (EINSTEIN-PE) 2007-03 to 2011-03 Phase 3 (E-switch-ic) Warfarin Non-inferior symptomatic VTE recurrence (primary endpoint) Similar major bleeding
Young et al. 2018 (SELECT-D) 2013-09-06 to 2016-12-22 Phase 3 (E-switch-ic) Dalteparin Seems to have superior rate of VTE recurrence over 6 months (primary endpoint) Inferior rates of clinically relevant non-major bleeding

Anticoagulation

3-, 6-, or 12-month course

References

  1. EINSTEIN Acute DVT: Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499-510. Epub 2010 Dec 3. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00440193; NCT00439725
  2. EINSTEIN-PE: Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A; EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 5;366(14):1287-97. Epub 2012 Mar 26. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00439777
  3. XALIA: Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E, Turpie AG. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. Lancet Haematol. 2016 Jan;3(1):e12-21. Epub 2015 Dec 8. link to original article PubMed NCT01619007
  4. EINSTEIN CHOICE: Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017 Mar 30;376(13):1211-1222. Epub 2017 Mar 18. link to original article PubMed NCT02064439
  5. SELECT-D: Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, Hale D, Dunn JA, Lyman GH, Hutchinson C, MacCallum P, Kakkar A, Hobbs FDR, Petrou S, Dale J, Poole CJ, Maraveyas A, Levine M. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018 Jul 10;36(20):2017-2023. Epub 2018 May 10. link to original article dosing details in abstract have been reviewed by our editors PubMed ISRCTN86712308
  6. EINSTEIN Junior: Male C, Lensing AWA, Palumbo JS, Kumar R, Nurmeev I, Hege K, Bonnet D, Connor P, Hooimeijer HL, Torres M, Chan AKC, Kenet G, Holzhauer S, Santamaría A, Amedro P, Chalmers E, Simioni P, Bhat RV, Yee DL, Lvova O, Beyer-Westendorf J, Biss TT, Martinelli I, Saracco P, Peters M, Kállay K, Gauger CA, Massicotte MP, Young G, Pap AF, Majumder M, Smith WT, Heubach JF, Berkowitz SD, Thelen K, Kubitza D, Crowther M, Prins MH, Monagle P; EINSTEIN-Jr Phase 3 Investigators. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020 Jan;7(1):e18-e27. Epub 2019 Nov 5. link to original article PubMed NCT02234843


Tinzaparin monotherapy

Regimen

Note: this agent has been withdrawn from the US market.

Anticoagulation

References

  1. LITE: Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G; LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006 Dec;119(12):1062-72. link to original article PubMed
  2. CATCH: Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA. 2015 Aug 18;314(7):677-86. link to original article PubMed NCT01130025


Warfarin monotherapy

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy Comparative Toxicity
Schulman et al. 2009 (RE-COVER) 2006-04 to 2008-11 Phase 3 (C) Dabigatran Non-inferior composite endpoint Similar major bleeding
Bauersachs et al. 2010 (EINSTEIN Acute DVT) 2007-03 to 2009-09 Phase 3 (C) Rivaroxaban Non-inferior VTE recurrence Similar major bleeding
Büller et al. 2012 (EINSTEIN-PE) 2007-03 to 2011-03 Phase 3 (C) Rivaroxaban Non-inferior symptomatic VTE recurrence (primary endpoint) Similar major bleeding
Agnelli et al. 2013 (AMPLIFY) 2008-08 to 2012-08 Phase 3 (C) Apixaban Non-inferior composite primary endpoint Higher rates of bleeding
Büller et al. 2013 (Hokusai-VTE) 2010-01 to 2012-10 Phase 3 (C) Edoxaban Non-inferior recurrent VTE rate Higher rates of bleeding
Lee et al. 2015 (CATCH) 2010-08 to 2013-11 Phase 3 (C) Tinzaparin Might have inferior composite outcome Similar major bleeding

Anticoagulation

Supportive therapy

  • Most protocols: Enoxaparin (Lovenox) 1 mg/kg SC once every 12 hours, given until INR greater than 2.0

3-, 6-, or 12- month course (see individual papers)

References

  1. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H; Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995 Jun 22;332(25):1661-5. link to original article PubMed
  2. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P, Eklund SG, Nordlander S, Lärfars G, Leijd B, Linder O, Loogna E; The Duration of Anticoagulation Trial Study Group. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med. 1997 Feb 6;336(6):393-8. link to original article PubMed
  3. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999 Mar 25;340(12):901-7. Erratum in: N Engl J Med 1999 Jul 22;341(4):298. link to original article PubMed
  4. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W; Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med. 2001 Jul 19;345(3):165-9. link to original article PubMed
  5. DOTAVK: Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S, Durieu I, Nony P, Sanson C, Boissel JP; Investigators of the "Durée Optimale du Traitement AntiVitamines K" (DOTAVK) Study. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001 May 22;103(20):2453-60. link to original article PubMed
  6. Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, Imberti D, Poggio R, Ageno W, Pogliani E, Porro F, Zonzin P; Warfarin Optimal Duration Italian Trial Investigators. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003 Jul 1;139(1):19-25. link to original article PubMed
  7. SOFAST: Kearon C, Ginsberg JS, Anderson DR, Kovacs MJ, Wells P, Julian JA, Mackinnon B, Demers C, Douketis J, Turpie AG, Van Nguyen P, Green D, Kassis J, Kahn SR, Solymoss S, Desjardins L, Geerts W, Johnston M, Weitz JI, Hirsh J, Gent M; SOFAST Investigators. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost. 2004 May;2(5):743-9. link to original article PubMed
  8. LITE: Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G; LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006 Dec;119(12):1062-72. link to original article PubMed
  9. RE-COVER: Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 Dec 10;361(24):2342-52. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00291330
  10. EINSTEIN Acute DVT: Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499-510. Epub 2010 Dec 3. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00440193; NCT00439725
  11. EINSTEIN-PE: Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A; EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 5;366(14):1287-97. Epub 2012 Mar 26. link to original article dosing details in abstract have been reviewed by our editors PubMed NCT00439777
  12. RE-MEDY: Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):709-18. link to original article PubMed NCT00329238
  13. AMPLIFY: Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. Epub 2013 Jul 1. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00643201
  14. Hokusai-VTE: Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406-15. Epub 2013 Aug 31. Erratum in: N Engl J Med. 2014 Jan 23;370(4):390. link to original article dosing details in manuscript have been reviewed by our editors PubMed NCT00986154
    1. Subgroup analysis: Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, Büller HR; Hokusai-VTE investigators. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 Aug;3(8):e379-87. Epub 2016 Jul 1. link to original article PubMed
  15. RE-COVER II: Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014 Feb 18;129(7):764-72. Epub 2013 Dec 16. link to original article PubMed NCT00680186
  16. CATCH: Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial. JAMA. 2015 Aug 18;314(7):677-86. link to original article PubMed NCT01130025


Additional information

  1. ↑ Circulation patient page about postthrombotic syndrome (PTS)
Retrieved from "https://hemonc.org/w/index.php?title=Venous_thromboembolism&oldid=94967"